Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > J&J sitting on cash, wanting acquisitions

<< Previous

Bullboard Posts

Next >>

Comment by Buckhenryon Sep 04, 2023 8:42pm

189 Views

Post# 35619196

RE:J&J sitting on cash, wanting acquisitions

I think canuckfan and unnoteable post continually to keep themselves pumped up. Their message has not changed in 4 years. Canuckfan's latest post is so full of ifs and buts and maybes. He reminds me of the guy that said... you know how you can tell a politician is lying.... his lips are moving.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec